Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.
Hims & Hers Health down as Super Bowl ad draws controversy
An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.
Stanislav Osipov on MSN7d
Drawing the Yankees Logo Step-by-Step Art Tutorial
January 31, 2025. More for You ...
Today7d
FDA approves first non-addictive pain medication
© 2025 NBCUniversal Media, LLCApple®, Apple logo® and App Store® are registered trademarks of Apple Inc.
Yahoo Finance21d
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The transdermal GFR (tGFR) methodology ...
Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System
Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption ...
How Tucker Carlson’s Nicotine Pouch Became the Latest Front in the Culture War
“You’ve gotta try this product,” Carlson said to Von, popping a mini-marshmallow-sized pouch into his mouth as the cameras started to roll. A sly grin spread across his face: “The truth is, Zyn is a ...
A new security seal of approval is coming to your smart home gadgets
The White House launched a new cybersecurity safety label, the U.S. Cyber Trust Mark, intended to help consumers make informed decisions on smart device safety.
Tucker Carlson Says His New Nicotine Pouches Could Launch a Revolution. So We Tried Them.
“You’ve gotta try this product,” Carlson said to Von, popping a mini-marshmallow-sized pouch into his mouth as the cameras started to roll. A sly grin spread across his face: “The truth is, Zyn is a ...
TMCnet9d
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
An archived copy of the webcast will be available for up to one year by visiting the “Investors & Media” section of the 4DMT website: https://ir.4dmoleculartherapeutics.com/events.